argenx SE ARGX

argenx has been through a volatile spell after a long run, and the recent swings now put a simple question in front of you as an investor: Is the current share price still in line with what the company's earnings can reasonably support? Over the past 5 years, argenx has delivered a share price gain of 185.3%, which puts a lot of weight on whether its earnings power has kept pace with that move. The company recently halted its Phase 3 Sjögren's trial for futility while reporting encouraging...

European equities traded in the US as American depositary receipts were tracking higher late Friday

Argenx (ENXTBR:ARGX) is back in focus after twin clinical updates. The company reported positive Phase 2 data for FB102 in celiac disease while deciding to halt its Phase 3 UNITY trial in Sjögren's disease. Over the past month argenx’s share price has come under pressure, with a 30 day share price return of down 18.5% and a 7 day move of down 16.2% around the UNITY trial halt. However, the 5 year total shareholder return of 172.3% shows long term holders have still seen strong gains,...

Argenx shares sink as the company discontinues a Phase 3 trial of Vyvgart in Sjögren’s disease. Is the selloff an opportunity for long-term investors?

Argenx unexpectedly scrapped a study of its drug, Vyvgart, in patients with Sjogren's disease on Thursday. The stock plummeted in response.

Healthcare stocks were lower late Thursday afternoon, with the NYSE Healthcare Index shedding 0.6% a

Immunovant is developing IMVT-1402 in an ongoing mid-stage study in Sjögren’s disease, which works the same way as Argenx’s efgartigimod.

Argenx says it discontinued a late-stage clinical trial in patients with Sjögren’s disease at the recommendation of an independent committee.

Shares in argenx SE (NASDAQ:ARGX) fell nearly 15% in New York on Thursday after it discontinued a late-stage trial of its drug Vyvgart in Sjögren's disease. Sjögren's disease is a chronic autoimmune condition characterized by immune-mediated destruction of the glands that produce tears and...

A monitoring board’s recommendation to stop the study for futility took Wall Street by surprise, removing one more ‘blockbuster expansion opportunity’ for Vyvgart.

The Belgian-Dutch biotech sank after an independent committee halted its pivotal UNITY study for futility, removing a major potential expansion market for Vyvgart.

European equities traded in the US as American depositary receipts fell late Thursday morning with t

argenx’s experimental CD122 inhibitor met its primary endpoint in a 126-patient study, demonstrating protection against gluten-induced intestinal damage and supporting advancement into late-stage clinical development. Key Investor Takeawaysargenx (NASDAQ:ARGX) reported positive Phase 2 celiac disease trial results for FB102, achieving statistical significance on the primary endpoint (p=0.

Key TakeawaysArgenx shares fell 11% after the company stopped its Phase 3 UNITY study of Vyvgart Hytrulo in Sjogren’s disease for futility. The sell-off looks overdone, since UNITY wasn’t due to read out until 2027 and Sjogren’s sales were unlikely to show up in the Street’s estimates through 2028.

Argenx said it would discontinue its Phase 3 Unity study of Efgartigimod SC in adults with moderate-to-severe Sjögren’s disease, an autoimmune condition.

Argenx SE (NASDAQ:ARGX) on Thursday delivered mixed clinical updates, announcing positive Phase 2 trial results for one experimental pipeline candidate alongside the failure of a Phase 3 study for another therapy. Phase 2 FB102 Celiac Disease Trial Success In its first clinical readout since acquiring Forte Biosciences in August 2026, the immunology company reported positive Phase 2 topline data for FB102 in adults with celiac disease. Celiac disease is a chronic autoimmune condition where eatin